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Abstract
Background. A marked elevation of serum leptin is
observed soon after the start of peritoneal dialysis
(PD), suggesting that leptin production may be
stimulated by this treatment. Glucose metabolism is
the major factor regulating leptin. The current study
was designed to test if glucose-based PD ﬂuids might
regulate leptin production in vitro.
Methods. 3T3-L1 adipocytes were exposed to a 50:50
mixture of dialysis solutions and medium M199
containing 10% serum for 48 h. Leptin secretion in
culture cell supernatants was measured by enzyme-
linked immunosorbent assay and leptin mRNA
content by northern blot analysis.
Results. The high glucose-based commercial dialysate
PD4 produced a higher leptin secretion compared with
an identical laboratory-manufactured dialysate (Lab-
D), but with a physiological glucose concentration of
5mM (P<0.05). Raising glucose concentration from
2.75 to 40mM in Lab-D induced a dose-dependent
increase in leptin secretion of 110±12% at 48 h
(P<0.001) and leptin mRNA (P<0.05; glucose 2.75
vs 40mM). Inhibition of UDP-N-acetylglucosamine
biosynthesis, with 6-diazo-5-oxo-norleucine added to
Lab-D, abolished most of the glucose-stimulated
leptin release and downregulated leptin gene expres-
sion. Furthermore, glucose-free Lab-D supplemented
with 1mM glucosamine, an intermediate product
in UDP-N-acetylglucosamine biosynthesis, increased
leptin secretion by 28±11% over control (P<0.05),
although without effect on leptin mRNA, after 48 h
of culture.
Conclusions. These results suggest that the PD-
induced hyperleptinaemia could, in part, be mediated
by the effect of glucose-based dialysis ﬂuids on leptin
production by adipocytes via activation of the
hexosamine biosynthetic pathway.
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Introduction
The adipocyte hormone leptin signals the body’s
nutritional status to regulatory centres in the hypo-
thalamus to regulate weight control. Leptin also has
distinct cytokine properties, responsible for effects on
renal cell growth, haematopoiesis and modulation of
the immune system [1], which have stimulated the
interest of the nephrologist.
Leptin circulates in proportion to fat mass. However,
patients with end-stage renal disease (ESRD) com-
monly have serum leptin levels several times higher than
would be expected for their adipose mass. The major
cause of uraemic hyperleptinaemia is reduced renal
clearance, although other factors associated with
ESRD may contribute to regulate leptin production in
this setting. Among patients undergoing renal replace-
ment therapy, those treated by peritoneal dialysis (PD)
have extraordinarily raised serum leptin, clearly out
of proportion to the fat accumulation observed in
these patients [2]. In addition, serum leptin increases by
189% within 1 month after starting PD treatment, in
spite of signiﬁcant leptin removal by the peritoneal
route [3]. It is therefore probable that factors other
than fat mass stimulate leptin production in PD.
There is abundant evidence that glucose metabolism
is the major regulator of leptin production [4]. In PD
patients, most dialysis solutions contain high glucose
concentrations. It is established that, during the
dwell, solutes in PD ﬂuids (especially glucose) are
transferred by passive diffusion through the peritoneal
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barrier [5] and, hence, come into contact with omental
adipocytes. Leptin is thought to be actively synthesized
by these cells, possibly through stimulatory effects
by the high glucose environment to which they are
exposed [6].
The aim of the present study was, therefore, to
investigate the effect of glucose-based PD solutions on
leptin secretion and leptin mRNA in cultured 3T3-
L1 adipocytes, to determine whether the previously
reported strong stimulation of leptin secretion by
glucose is still important in the context of dialysis ﬂuids.
Subjects and methods
Dulbecco’s modiﬁed Eagle’s medium (DMEM), M199, fetal
bovine serum (FBS) and sodium pyruvate were purchased
from Invitrogen (Basle, Switzerland). Penicillin–streptomycin
was obtained from Seromed, Switzerland. Insulin, dexa-
methasone, 3-isobutyl-1-methylxanthine (IBMX), glucosa-
mine and 6-diazo-5-oxo-L-norleucine (DON) were purchased
from Sigma-Aldrich (Basle, Switzerland). Cell culture plastics
were supplied by Falcon (Geneva, Switzerland).
Choice of in vitro model
In the design of this study, four in vitro models of adipose
tissue were tested. Human omental adipocytes were isolated
by collagenase digestion from omental biopsies from PD
patients undergoing catheter insertion. The viable non-
adherent adipocyte suspensions obtained were unsuitable,
however, as viability declined after only 12 h in suspension. In
contrast, pre-adipocytes isolated from the biopsies above
were adherent to plastic ﬂasks, proliferated and differentiated
in culture. However, the small number of cells available from
each tissue donor precluded their use in routine experiments.
Omental adipose tissue explants (2–5mm in diameter)
obtained from further donors were also cultured for 48 h
and showed signiﬁcant, but widely varying, leptin secretion,
owing to wide variations in the ratio of adipose to connective
tissue in the samples. The present study was, therefore,
performed in the 3T3-L1 pre-adipocyte culture model that has
been characterized previously for studies of leptin secretion in
this laboratory [7,8].
3T3-L1 ﬁbroblasts were grown to conﬂuence and differ-
entiation to adipocytes was stimulated by incubation with
IBMX, dexamethasone and insulin, as described previously
[7,8]. At this stage, phase-contrast microscopy showed that all
the cells exhibited typical adipocyte morphology without any
apparent ﬁbroblast contamination. For leptin mRNA studies,
cells were treated as reported previously [8].
Leptin protein quantitation
Leptin concentrations in cell culture media were determined
using a sandwich enzyme-linked immunosorbent assay for
mouse leptin (Quantikine M; R&D Systems, Minneapolis,
MN, USA), as described previously [7].
Analysis of leptin mRNA
Total RNA was extracted as described in an earlier
study [8]. Leptin mRNA was determined by northern
analysis according to standard methods used in this
laboratory [9].
Membranes were hybridized with a [32P]dCTP-labelled
cDNA probe for mouse leptin, generated as described
previously [8]. RNA loading was normalized using a cDNA
probe for cyclophilin, which was generously supplied by the
Institute of Pharmacology and Toxicology, University of
Lausanne, Switzerland.
Experimental design
For leptin secretion studies, 3T3-L1 adipocytes were exposed
for 48 h to a 50:50 mixture of the PD dialysis solution and
M199 with 10% FBS containing 500 IU/ml penicillin,
500mg/ml streptomycin and 0.5mmol/l sodium pyruvate.
The dilution of PD ﬂuid in this way was used to mimic the
equilibration of dialysis solutions that occurs early after their
infusion into the peritoneal cavity, i.e. a fall in glucose and
lactate concentrations and osmolality and an increase in pH
[10]. A commercial dialysate with a high glucose concentra-
tion (1.36%, PD4; Baxter Healthcare Ltd) or a laboratory-
manufactured, ﬁlter-sterilized dialysate (Lab-D) of identical
electrolyte composition and pH to PD4 were used. The use of
the laboratory-made solution enabled the D-glucose concen-
tration of the ﬁnal test medium to be varied. A 1.36% glucose
solution contains 76mM D-glucose and, hence, after dilution
50:50 with M199 (glucose concentration: 5.5mM), the test
medium has a ﬁnal glucose concentration of 40.75mM.
Glucose concentrations in Lab-D were varied between 2.5
and 40mM, allowing assessment of the effect of glucose over
a pathophysiological concentration range. Mannitol was used
in place of glucose in Lab-D as an osmotic control (Mann) to
match PD4’s osmolality.
Aliquots of cell supernatants were collected at 24 and 48 h.
The samples were frozen at 20C for subsequent leptin
assays. Cell monolayers were lysed by scraping the cells from
the culture plate into 0.5M sodium hydroxide. Total protein
was measured using a modiﬁed Lowry technique (BioRad DC
protein assay; BioRad).
For leptin mRNA experiments, the cells were treated as
above for 12, 24 and 48 h. After each of these time points,
1.5ml phenol guanidine isothiocyanate reagent (Trizol;
Invitrogen) was added. The ﬂasks were subsequently stored
at 20C prior to RNA extraction.
Investigation of the hexosamine pathway
The hexosamine biosynthetic pathway, which is known to use
the inwards intracellular glucose ﬂux to regulate leptin
production [11], was investigated in two ways: (a) the addition
of DON, an inhibitor of the regulatory enzyme glutamine:-
fructose-6-phosphate amidotransferase (GFAT), to glucose-
based Lab-D in order to reduce the ﬂux through this pathway;
and (b) the use of D-glucosamine (2 amino-2-deoxy-D-glucose)
that, after transport into the cell and phosphorylation, acts
downstream of GFAT and, hence, increases the ﬂux through
this pathway. Glucosamine is supplied as hydrochloride salt,
which caused a dose-dependent fall in pH in preliminary
experiments. As acidosis per se decreases leptin production in
this cell line [7,8], the pH of the glucosamine-supplemented
media was adjusted by the addition of NaHCO3. A further
problem is that glucose and glucosamine may compete for the
same plasma membrane transporter (GLUT-4), potentially
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blunting effects of glucosamine. Experiments were, there-
fore, conducted in glucose-free dialysis solutions with 1mM
pyruvate as an alternative energy source. Under these con-
ditions, the percentage of lactate dehydrogenase (LDH)
released was unaffected (see below) and leptin concentration
in the medium was greater at 48 h than at 24 h, demonstrating
the continued viability of the cells.
Assessment of cell viability
Cell viability was assessed by measurement of LDH activity
released into the cell culture supernatant using a commercial
spectrophotometric assay (DG1340-K; Sigma). Cytotoxicity
was expressed as the LDH activity in culture supernatant as a
percentage of total LDH activity in the cells.
Statistical analyses
Data were expressed as means±SEM. For comparison of
means between two groups, an unpaired t-test was used.
Comparison of means between multiple groups was by
analysis of variance with Duncan’s multiple range test.
Statistical signiﬁcance was deﬁned as P<0.05.
Results
Effect of PD4 on leptin secretion
The high glucose-containing dialysate PD4 caused
signiﬁcantly higher leptin release at 48 h, compared
with Lab-D containing a physiological glucose
concentration of 5mM. In contrast, the osmotic
control Mann did not produce the same effect
(Figure 1).
Effects of glucose concentration on leptin in
laboratory-manufactured dialysates
Increasing the glucose concentration from 2.75 to
40mM in Lab-D increased leptin concentration in the
cell supernatants by 110±12% in a dose-dependent
fashion at 48 h (P<0.001) (Figure 2). Leptin mRNA
content, as assessed by northern blot analysis, was also
upregulated (P<0.05; glucose 20 and 40 vs 2.75mM).
Although there was a trend towards an increase of
leptin mRNA at 12 h, the effect became signiﬁcant at
24 h (Figure 3), preceding the effect on secretion, which
in turn reached statistical signiﬁcance at 48 h. This time
sequence strongly suggests that the leptin-stimulating
effect by glucose-based PD ﬂuids may be mediated
through a transcriptional effect. To test for a possible
effect of sterilization technique on PD ﬂuid-induced
leptin secretion, the response of cells exposed to
commercially produced PD4 (heat sterilized) was
directly compared to that with Lab-D (ﬁlter sterilized)
containing a similar glucose concentration (40mM).
No differences were found (n¼ 3, pool of 14–16 wells
for each condition; data not shown).
Finally, the intracellular protein content of the
cell lysates was not signiﬁcantly affected by any
of the dialysates tested. Therefore, the observed
changes in leptin protein secretion and gene expres-
sion could not be accounted for by non-speciﬁc
effects on cell growth. Moreover, neither PD4 nor
any laboratory-manufactured (glucose- or mannitol-
based) solutions were associated with signiﬁcant cell



















Fig. 1. Effect of different PD ﬂuids on leptin secretion. 3T3-L1
adipocytes in six-well plates were incubated for 48 h in PD4
(glucose 1.36%) or laboratory-manufactured dialysates (Lab-D)
identical to PD4 but with a glucose concentration of 5mM.
Mannitol (Mann) was used in laboratory-manufactured dialysate
as an osmotic control. Solutions were diluted 50:50 with M199.
Results shown are means±SEM of four independent experiments
























Fig. 2. Effect of glucose concentration in dialysates on leptin
secretion. 3T3-L1 adipocytes in six-well plates were incubated in
Lab-D at various glucose concentrations. Solutions were diluted
50:50 with M199. The ﬁnal glucose concentration in the test media
was as shown. Results shown are those obtained at 48 h of
incubation (means±SEM of three independent experiments; pool
of 22–26 culture wells for each set of conditions). *P<0.001 vs
2.75mM glucose.
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Modulation of the hexosamine biosynthetic pathway
The hexosamine biosynthetic pathway has been pro-
posed as a nutrient sensor linking the incoming glucose
ﬂux with leptin gene expression and secretion [11].
Whether this pathway is still involved in the presence of
unphysiological PD ﬂuids was therefore determined.
DON (20 mmol/l), added to Lab-D with a high
glucose concentration of 20mM, signiﬁcantly reduced
leptin secretion at 48 h, abolishing most of the leptin-
stimulating effect of glucose (Figure 4). Under identical
conditions, the addition of DON to Lab-D also
decreased leptin mRNA over a 48 h time course
(Figure 5). This effect could not be accounted for by
cell toxicity, since LDH release in the cell supernatants
was insigniﬁcant.
High glucosamine concentrations of 10 and 20mM
added to Lab-D suppressed leptin secretion as shown
previously [12]. In contrast, D-glucosamine at low doses
of 0.1 and 1mM signiﬁcantly increased leptin secretion
over control by 24±8% and 28±11%, respectively, at
48 h (Figure 6) in Lab-D with no extracellular glucose.
However, the addition of D-glucosamine did not affect
leptin mRNA, suggesting that, under these conditions,
the glucosamine-induced effect on leptin occurs at a
post-transcriptional level (Figure 7).
Discussion
Effects of glucose dialysate
It is well established that, in patients treated by PD, the
solutes in PD ﬂuids (including glucose) are transferred
by passive diffusion through the peritoneal barrier [5].
As a result, cells located in the submesothelial space,
e.g. resident ﬁbroblasts and macrophages, have been
shown to be activated by solutes from PD ﬂuids [13].
We therefore hypothesized that adipocytes from the
omentum, which are in intimate contact with the
mesothelial cell layer, also interact with chemical
components from PD ﬂuids, especially glucose. The
precise glucose concentration experienced by omental
adipocytes in vivo in patients treated with high glucose
PD ﬂuids is unknown, but it is certainly high. The
evidence for this is that the extracellular glucose
concentration is signiﬁcantly elevated even at sites
well beyond the submesothelial space and, conse-
quently, systemic hyperglycaemia is readily detectable
in patients using glucose-based PD ﬂuids [14].
The resulting high glucose concentration in the vicinity
of omental adipocytes is regarded as sufﬁcient to
stimulate leptin secretion in such patients [6].
This study provides the ﬁrst evidence that glucose-
based dialysis solutions do, indeed, stimulate leptin
production from cultured adipocytes (Figure 1), an
effect that is attributable to glucose (Figure 2) but not
to hyperosmolarity (Figure 1) or to agents generated by
heat sterilization of the dialysate. This marked effect of
glucose on leptin secretion was obtained in spite of the
known inhibitory effect of the low pH [7,8] that occurs
in PD solutions.
The hexosamine pathway and glucose dialysate
As the ﬂux through the hexosamine pathway of
glucose metabolism has been suggested previously as
a mediator of the effect of glucose on leptin synthesis
and secretion [11], we tested whether modulation of this
pathway could still affect leptin protein release and
leptin mRNA in the context of dialysis ﬂuid.
DON, which reduces hexosamine pathway ﬂux
by inhibition of GFAT, was shown nearly to
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Fig. 3. Effect of increasing glucose concentration in dialysates on
leptin mRNA. 3T3-L1 adipocytes in 25-cm2 ﬂasks were incubated
in Lab-D at various glucose concentrations. Solutions were diluted
50:50 with M199. The ﬁnal glucose concentration in the test media
was as shown. Leptin mRNA was assessed by northern blot.
Results show a representative blot from three separate experiments




















Fig. 4. Effect of the addition of DON in laboratory-manufactured
dialysates on leptin secretion. Cells were incubated for 48 h in
Lab-D diluted 50:50 with M199. The ﬁnal glucose concentration in
the test media was as shown. Results shown are those obtained at
48 h of incubation (means±SEM of three independent experiments;
pool of 18–20 culture wells for each set of conditions). *P<0.05,
5 vs 20mM glucose. **P<0.05, DON vs control (20mM glucose).
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glucose-based dialysates. This was associated with a
decrease in leptin mRNA, suggesting that GFAT
modulates leptin production through effects on tran-
scription or stability of leptin mRNA. To test the
hypothesis that increasing the metabolic ﬂux into the
hexosamine pathway would result in increased leptin
production, we incubated cultured adipocytes in Lab-D
supplemented with glucosamine. Under conditions
designed to avoid potential interference through
artefactual glucosamine actions (fall of pH and ATP
depletion), glucosamine signiﬁcantly increased leptin
secretion over the control value at 48 h.
Our data in part conﬁrm previous studies that
investigated this issue [15,16]. However, the current
study has examined these effects speciﬁcally in the
context of PD ﬂuids. Low pH, high lactate and high
osmolarity in dialysates inhibit cell function in many
cell types [10]. Therefore, the maintenance of leptin
responses to subtle modulations of the hexosamine
pathway (Figures 4–7) in the presence of dialysate is
noteworthy. The only discrepancy was that glucosa-
mine had no effect on leptin mRNA, which is not in
agreement with Zhang et al. [16], who demonstrated
that glucosamine increased leptin gene promoter
activity in 3T3-L1 adipocytes. It should be emphasized
that, to avoid unwanted side effects, glucosamine was
used in the present study only at a fairly low dose
yielding a stimulation of leptin secretion considerably
smaller than that observed with high concentrations of
glucose. We have shown previously in studies with
glucose transport inhibitors in these cells [8] that large
changes in glucose inﬂux lead to decreases in both
leptin secretion and leptin mRNA, whereas more
moderate inhibition of glucose inﬂux decreases leptin
secretion without detectable effect on mRNA levels. In
response to moderate changes in glucose or glucosa-
mine ﬂux, a non-transcriptional mechanism may be
responsible for changes in leptin secretion, possibly
through effects at the level of translation. Reports that
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Fig. 5. Effect of the addition of DON in laboratory-manufactured dialysates on leptin mRNA. Cells were incubated for 48 h in Lab-D
diluted 50:50 with M199 with a ﬁnal glucose concentration of 20mM. In Panel A, DON at 20 mM was added to the test medium, whereas
in panel B, experiments were conducted without DON (control). Leptin mRNA was assessed by northern blot. Representative blots are
shown. Numerical results are means of six culture ﬂasks pooled from two independent experiments. *P<0.05 vs 0 h.





















free medium)  
Fig. 6. Effect of glucosamine in laboratory-manufactured dialysates
on leptin secretion. Cells were incubated for 48 h in glucose-free
Lab-D diluted 50:50 with glucose-free DMEM. Glucosamine was
added to test media (concentrations as shown) and leptin release
was measured over control (C). Results shown are means±SEM of
four separate experiments (pool of 8–22 culture wells for each set
of conditions). *P<0.05 vs control.
Leptin
Cyclophilin
C    0.1 1Glucosamine, mM
Fig. 7. Effect of glucosamine in laboratory-manufactured dialysates
on leptin mRNA. Cells were incubated for 48 h in glucose-free
Lab-D diluted 50:50 with glucose-free DMEM, with glucosamine
(concentrations as shown) or without (C). Results show a
representative blot from four separate experiments.
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the hexosamine pathway and its resulting O-Glc-NAc
glycosylation of the eukaryotic initiation factor-2
binding protein p67 can initiate translation [17] support
this view.
Limitations of the present culture model
Incubation conditions. In clinical practice, PD ﬂuids
have unphysiologically high glucose concentrations;
however, these concentrations are not sustained in the
peritoneal cavity since they rapidly fall to 38% of initial
values at 4 h [10]. For these reasons, our experiments
were restricted to the pathophysiological range of
2.5–40mM ﬁnal glucose concentration. The stimulat-
ing effects of glucose-based dialysates were seen at 24 h
(leptin mRNA) and 48 h (leptin protein release) and
these incubation times are longer than the dwell times
in PD. It must be emphasized that even the best study
design employing cultured cells in vitro may not exactly
mimic clinical practice. However, potential effects seen
in vitro at 24 and 48 h may be relevant, since patients
on PD repeatedly replace the dialysate with a fresh
solution.
Choice of cell line. As a clonal cell line, 3T3-L1 cells
have the advantage of a homogeneous cell population
allowing precise comparisons of deﬁned treatments,
without the confounding factor of variation between
different donors. Nevertheless, the 3T3-L1 pre-
adipocyte model (like all in vitromodels) has limitations
in studying the response of omental adipocytes to PD
ﬂuids. This is a mouse rather than human cell line and
has been used previously as a model of subcutaneous
rather than visceral (omental) adipocytes [18].
However, the endocrine effects of cell lines (including
3T3-L1) in vivo, when implanted in various fat depots,
vary considerably depending on the location of
implantation [19]. This means that the in vivo environ-
ment rather than the nature of the adipocyte cell line
per se is the crucial factor. It is not certain, therefore,
that adipocytes from other sources (e.g. visceral
adipocytes from PD patients), if grown in vitro in
isolation, would have provided a more accurate model
than 3T3-L1 adipocytes. Furthermore, omental adipo-
cytes are more leptin-responsive to nutrient stimuli
in vivo than are subcutaneous adipocytes [20].
Therefore, even if 3T3-L1 do behave more like sub-
cutaneous adipocytes than visceral adipocytes [18], this
may mean that the glucose effect observed simply
underestimates the effect that would be seen in visceral
adipocytes. It has also been shown that leptin responses
to changes in glucose availability are qualitatively
similar in rat [4], human subcutaneous [15] and 3T3-L1
adipocytes [16], suggesting that marked qualitative
differences between cell lines in the glucose response of
leptin are unlikely.
It should be emphasized, however, that results
obtained with any single cell line must be interpreted
with caution and it will, therefore, be interesting to
see whether results like those in the present study are
also observed in future studies with human adipocyte
lines.
In summary, this study provides evidence that
glucose contained in dialysis ﬂuids stimulates leptin
production from cultured adipocytes and that this
effect is at least partly mediated through the hexosa-
mine biosynthetic pathway. The data support the
notion that leptin is actively synthesized by intra-
abdominal adipose tissue of patients undergoing PD,
thus, contributing to sustained hyperleptinaemia
associated with this treatment.
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